Empagliflozin Benefited Type 2 Diabetes Patients with CKD
Key clinical point: Empagliflozin was found to improve renal outcomes in patients with type 2 diabetes and chronic kidney disease.
Major finding: Compared with patients in the placebo group, those in the empagliflozin group demonstrated a 39% reduction in new onset or worsening of nephropathy (HR, 0.61; P less than .0001).
Data source: An analysis of data from 7,020 patients enrolled in the EMPA-REG OUTCOME trial, including 2,333 in the placebo group and 4,687 in the empagliflozin group who were followed for a median observation time of 3.1 years.
Disclosures: The study was supported by Boehringer Ingelheim and Eli Lilly. Dr. Wanner disclosed numerous financial ties to industry.
AT KIDNEY WEEK 2015
The most common adverse events in patients with CKD related to the study drug were urinary tract infections and genital infections, but there were no detectable signals on acute kidney failure, hyperkalemia, or bone fracture.
“Empagliflozin reduces cardiovascular death, all-cause mortality, and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk,” Dr. Wanner concluded. “Safety and tolerability of empagliflozin in patients with CKD at baseline were similar to the overall trial population and consistent with previous clinical trials.”
The study was supported by Boehringer Ingelheim and Eli Lilly. Dr. Wanner disclosed numerous financial ties to industry.
